Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Reed (NPI 1477585347)

Field	Value
Entity Type	Individual
Organization	Mark Reed
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Gynecologic Oncology Physician
NPI Enumerated	July 7, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s Medicare business is the sole recorded payer activity: lifetime Medicare revenue is $2.3M and there is no Medicaid billing on file, making the practice effectively single‑payer (Medicare) for the available data. The provider’s NPI was enumerated on 2006-07-07 (~20 years ago), indicating a long-tenured practice likely established in the local market.

Revenue is highly concentrated in a small number of oncology drug codes: the precomputed top 3 Medicare codes (J9271, J9144, J0897) account for 58.6% of the provider’s total Medicare revenue, with J9271 alone representing 41.3% of Medicare revenue. That concentration signals dependency on a few high-cost injectable therapies rather than broad fee‑for‑service volume.

The specific code mix points to an office-based oncology infusion practice with gynecologic oncology surgical capability. High-revenue chemotherapeutic and immunotherapy drugs (J9271 pembrolizumab, J9144 daratumumab, J0897 denosumab, plus biosimilar bevacizumab Q5107) dominate revenue while chemotherapy administration/add-on codes (96413, 96367, 96365, 96417) and a hysterectomy code (58571) also appear, indicating combined infusion and procedural services.

Competitive standing on the top revenue driver is solid but not dominant: J9271 (pembrolizumab) is 41.3% of revenue and the provider ranks #363 of 1841 nationally (80th percentile) with volume characterized as typical/unremarkable. In other words, the practice delivers substantial pembrolizumab volume relative to many peers but does not sit at the extreme top of national volume.

Several administration and procedure codes are statistical outliers on the high side, suggesting above‑typical infusion throughput: 96413 ranks #532 of 7514 (93th percentile, labeled notably above typical national volume), 96367 ranks #91 of 4032 (98th percentile, labeled notably above typical national volume), and 96417 ranks #201 of 3014 (93th percentile, labeled notably above typical national volume). The presence of these high-percentile administration codes supports the interpretation of an active infusion practice with frequent multi‑drug or extended infusions.

Biosimilar use and selective national standing are visible in the drug mix: Q5107 (bevacizumab biosimilar) accounts for 6.7% of Medicare revenue and ranks #8 of 78 nationally (91th percentile, typical/unremarkable volume), while Q5123 (rituximab biosimilar) and other injectables appear at lower shares. This pattern indicates meaningful uptake of biosimilars within a relatively small national cohort of providers who bill these specific biosimilar codes.

Non‑drug professional services contribute modestly but are concentrated in higher‑complexity visits and procedures: 99215 (217 claims, $25.6K revenue) ranks #10338 of 145531 (93th percentile, typical/unremarkable volume) and 58571 (34 claims, $23.1K revenue) ranks #45 of 754 (94th percentile, notably above typical national volume). These data signal that the provider manages complex outpatient encounters and performs a nontrivial number of gynecologic surgical procedures relative to peers.

From a payer or network perspective, the combination of a nearly exclusive Medicare revenue base, heavy reliance on a few high-cost oncology drugs (58.6% concentrated in the top 3 codes), and above‑typical infusion administration volumes suggests the practice is best characterized as a Medicare‑focused oncology infusion and surgical provider. That profile is important for contracting, utilization management, and network adequacy discussions because drug cost exposure is concentrated and Medicaid exposure is effectively absent.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

94 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,700	$40	$890.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,760	$40	$218.9K
J0897	Injection, denosumab, 1 mg	8,520	$20	$153.4K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	6,590	$20	$145K
J9047	Injection, carfilzomib, 1 mg	3,090	$40	$111.2K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	2,350	$40	$82.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,210	$40	$79.6K
J1439	Injection, ferric carboxymaltose, 1 mg	66,750	$1	$66.8K
J1437	Injection, ferric derisomaltose, 10 mg	3,900	$20	$62.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	730	$90	$62.2K

Showing 1–10 of 94

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 94 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Mark Reed — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

94 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	50	17,400	$40	$776.1K
J9144	18	20	10,080	$40	$466.3K
J1569	19	30	3,030	$40	$175.2K
J9047	3	10	3,090	$40	$117.8K
J1437	10	20	3,700	$20	$86.3K
J0897	35	240	2,940	$20	$85K
Q5107	2	20	2,990	$20	$77.6K
Q5123	4	10	1,960	$40	$70.9K
J0881	45	70	19,050	$1	$54.4K
J2506	9	40	430	$80	$46.7K

Showing 1–10 of 94

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Reed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Shelby County Health Care Corporation	TN	General Acute Care Hospital	$0	$56.1M
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Mark Reed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Mark Reed — Billing Profile & Reimbursement Data

Sign up for Mark Reed — Billing Profile & Reimbursement Data policy alerts

Mark Reed — Billing Profile & Reimbursement Data

Sign up for Mark Reed — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References